BridgeBio Pharma Inc. (BBIO) appoints Thomas Trimarchi as CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
BridgeBio Announces CFO Succession
March 17, 2025 4:01 PM EDTPALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of Principal Financial Officer and will continue to lead the Companys FP&A and accounting operations.
Brian... More
